Immuno-Oncology 360° Agenda 2026 Page 2

Day Two: Wednesday, February 11, 2026

List/Print View

Grid View

Showing Events in 1 Track from 07:45am to 08:45am

Morning Remarks

7:45AM - 8:15AM

Registration & 1:1 Meetings

8:15AM - 8:20AM

Co-Chairs’ Welcome

Co-Chairs:

Charles Drake, MD, PhD, VP, Immuno-Oncology, J&J Innovative Medicine

Naiyer Rizvi, MD, CMO, Synthekine

8:20AM - 8:45AM

Fireside Keynote: What’s Next in Immuno-Oncology - A Visionary Conversation with Dr. Ira Mellman

Fireside Guest:

Ira Mellman, PhD, President of Research, Parker Institute for Cancer Immunotherapy (PICI)

Moderated by:

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Showing Events in 1 Track from 08:45am to 09:25am

State of the IO Market, Investments and Deals Plenary

8:45AM - 9:05AM

IO Capital Markets Outlook for Biotechs & IO

Speaker:

Lorenzo Paoletti, MBA, Managing Director, Biopharma Investment Banking, Bank of America

9:05AM - 9:25AM

M&A Strategies in Biotech: Navigating the Path to Acquisition

Speaker:

Rick Aldridge, MBChB, Managing Director, Healthcare Investment Banking, BMO Capital Markets

Showing Events in 1 Track from 09:25am to 10:05am

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings

9:25AM - 10:05AM

Morning Networking Break

Showing Events in 1 Track from 10:05am to 10:50am

IO360° Biotech Showcase

10:05AM - 10:50AM

IO360° Biotech Showcase

Speakers:

Shawn Davis, PhD, CEO, Liberate Bio

Upendra Marathi, PhD, MBA, CEO, 7 Hills Pharma Inc.

Jean-Francois Millau, PhD, CEO & Co-Founder, TATUM Biosciences

Gerben Moolhuizen, CEO, Abalos Therapeutics

Jonathan Northrup, MBA, Co-Founder & CEO, Stingray Therapeutics, Inc.

Tarek Ali Zaki, CEO & Co-Founder, OncoPrecision, Inc.

Participating Companies:

Showing Events in 1 Track from 10:50am to 10:55am

5 Minute Health Break

10:50AM - 10:55AM

5 Minute Health Break

Showing Events in 1 Track from 10:55am to 12:15pm

State of the IO Market, Investments and Deals Plenary (Continued)

10:55AM - 11:35AM

What Makes a Smart Deal in IO? Navigating Capital, Competition, and Global Innovation

Moderated by:

Andrew Baum, MD, Chief Strategy and Innovation Officer, Pfizer

Panelists:

Jeffrey M. Bockman, PhD, Expert Advisor and EVP, Oncology, Lumanity

Deepa Pakianathan, PhD, Managing Partner and CEO/Co-Founder, Delphi Ventures / Stealth Oncology Company

Gayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZeneca

Markus Werner, PhD, Head, Search & Evaluation, Oncology, Novartis

Evan Zisholtz, JD, VP, Global Business Development, Immunai

11:35AM - 12:15PM

IO Investment Trends: What’s Driving Capital in 2026?

Moderated by:

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Panelists:

Reni Benjamin, PhD, Managing Director, Citizens Capital Markets and Advisory

Kalli Dircks, Managing Director, Global Capital Markets, Morgan Stanley

Rajiv Kaul, Portfolio Manager, Equity Division, Fidelity Investments

I-hung Shih, PhD, MBA, Managing Director & Portfolio Manager, Eventide Asset Management

Showing Events in 1 Track from 12:15pm to 01:15pm

Lunch

12:15PM - 1:15PM

Lunch & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 01:20pm to 03:20pm

TRACK 1: Breakthroughs in Translational Science, Imaging & Biomarkers

1:20PM - 1:40PM

VIP Talk: Targeting Myeloid Cells for Therapeutic Enhancement

Speaker:

Miriam Merad, MD, PhD, Chair, Department of Immunology and Immunotherapy, Director, Marc and Jennifer Lipschultz Precision Immunology Institute, Director, Mount Sinai Human Immune Monitoring Center, Mount Sinai School of Medicine

1:40PM - 2:00PM

Next Gen 18F CD8-PET Imaging: Transforming IO Development and Patient Care

Speakers:

Stephane Champiat, MD, PhD, Medical Oncologist, The University of Texas MD Anderson Cancer Center

Kristen Wangerin, PhD, Senior Imaging Technology Leader, Pharmaceutical Diagnostics, GE HealthCare

2:00PM - 2:20PM

Engineering the Optimal T Cell Engager: From Molecular Design to Clinical Translation

Speaker:

Julie Bailis, PhD, Associate Vice President, Acting Head of Oncology Research, Amgen

2:20PM - 2:40PM

Reserved for Natera

2:40PM - 3:00PM

Leveraging Synthetic Antigens to Create Universal Immunotherapies for Solid Tumors

Speaker:

Barbra Sasu, PhD, CSO, Dispatch Bio

3:00PM - 3:20PM

First-in-Human Imaging of a Zirconium-89-Labeled Monoclonal Antibody in Small Cell Lung Cancer

Speaker:

Diederik Grootendorst, PhD, Director, Global Oncology Imaging, Bristol Myers Squibb

TRACK 2: IO Cell Therapy Plenary

1:20PM - 2:00PM

In Vivo Cell Therapy: Rewriting the Rules of Cell-Based Treatment

Moderator:

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

Panelists:

Gwendolyn Binder, PhD, President, Science & Technology, Cabaletta Bio

Adrian Bot, MD, PhD, EVP, R&D and Founding CSO, Capstan Therapeutics

Dong Geng, PhD, SVP, Global EDD and Preclinical Development, Legend Biotech

Jacek Lubelski, PhD, Chief Technology Officer, NanoCell Therapeutics

2:00PM - 2:20PM

Islet Transplantation for Type 1 Diabetes

Speaker:

Fouad Kandeel, MD, PhD, Arthur D Riggs Distinguished Chair in Diabetes and Metabolism Research, Professor and Chair Department of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope

2:20PM - 2:40PM

iPSC Therapy for Parkinson’s

Speaker:

Seth Ettenberg, PhD, President and CEO, BlueRock Therapeutics

2:40PM - 3:20PM

iPSC 2.0: From Promise to Productization

Speakers:

Dhavalkumar Patel, MD, PhD, EVP & CSO, Sana Biotechnology

Gregory Russotti, PhD, Chief Technology and Manufacturing Officer, Century Therapeutics

Bahram (Bob) Valamehr, PhD, President & CEO, Fate Therapeutics

Showing Events in 1 Track from 03:20pm to 04:00pm

Afternoon Networking Break

3:20PM - 4:00PM

Afternoon Networking Break & 1:1 Partnering Meetings

Showing Events in 3 Tracks from 04:00pm to 05:30pm

TRACK 1: Translational Science & Biomarkers – Expanding Therapeutic Horizons

4:00PM - 4:20PM

From Oncology to Autoimmune Diseases: Expanding the Impact of Plasma-Cell Directed Therapies

Speaker:

Prof Dr Med Ricardo Grieshaber-Bouyer, MHBA, Head of the Clinical Trial Unit; Professor of Clinical Systems Immunology, Department of Internal Medicine 3 – Rheumatology and Immunology;, FAU Erlangen-Nürnberg and University Hospital Erlangen

4:35PM - 4:55PM

Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin

Speaker:

Lan Huang, PhD, Chairwoman, CEO & Co-Founder, BeyondSpring Inc.

5:10PM - 5:30PM

Successful Treatment of HPV-associated Recurrent Respiratory Papillomatosis (RRP) with HPV-specific Immunotherapy: Results from a Pivotal Phase 1/2 Clinical Trial

Speaker:

Scott M Norberg, DO, Associate Research Physician, Center for Immuno-Oncology; Head, Solid Tumor Cellular Therapy Group, Center for Cancer Research, National Cancer Institute, National Institute of Health (NIH)

TRACK 2: Translational Science and Biomarkers - Targeting Immune Mechanisms

4:00PM - 4:20PM

RIPTAC: A New Frontier in Targeted Protein Degradation – Insights from J&J

Speaker:

Charles Drake, MD, PhD, VP, Immuno-Oncology, J&J Innovative Medicine

4:35PM - 4:55PM

Targeting Fascin to Disrupt Metastasis and Reinvigorate Anti-Tumor Immunity

Speaker:

Jose Jimeno, MD, PhD, Chief Medical Officer, Novita Pharma

5:10PM - 5:30PM

Reserved Session for Biopharma / Academia

TRACK 3: IO Cell Therapy Plenary

4:00PM - 4:35PM

Rebuilding TCR-T Cell Therapy: Novel Targets, Smarter Circuits, and the Road to Universality

Moderator:

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

Panelists:

Reagan Jarvis, PhD, CEO & Scientific Founder, Anocca

Harpreet Singh, PhD, CEO, Immatics

Eric Tran, PhD, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute

Elizabeth Wood, PhD, CEO & Founder, Jura Bio, Inc

4:35PM - 5:10PM

Beyond the Bench: AI Integration Across the Cell Therapy Pipeline

Panelists:

Benjamin Greenbaum, PhD, Director, Computational Immuno-Oncology, Memorial Sloan Kettering Cancer Center

Elizabeth Wood, PhD, CEO & Founder, Jura Bio, Inc

5:10PM - 5:30PM

The State of TIL Therapy: Innovation, Lessons Learned, and What’s Next

Moderator:

Kimberly Schluns, PhD, Sr Director, Kite Pharma

Fireside Guests:

Igor Bilinsky, PhD, Chief Operating Officer, Iovance Biotherapeutics

Parameswaran Hari, MD, CMO, Obsidian Therapeutics

Anna Truppel-Hartmann, MD, Chief Medical Officer, KSQ Therapeutics

Showing Events in 1 Track from 05:35pm to 06:10pm

IO360° Cancer Immunotherapy Debate

5:35PM - 6:10PM

IO360° Annual Debate: Multifunctional vs. Monospecific Antibodies - Which Defines the Future of IO?

Led by:

Daniel S Chen, MD, PhD, Founder, Engenuity Life Sciences

Debate Participant:

Michael Curran, PhD, Professor, Department of Immunology / Founder, MD Anderson Cancer Center / ImmunoGenesis, Inc

Day One

Tuesday, February 10, 2026

Day Three

Thursday, February 12, 2026

Day One

Day Three

Subscribe for More Information